Research Library

In a new brief, McClain Sampson, fellow in Maternal and Reproductive Health, and co-author Priscilla P. Kennedy summarize how the recent Texas Medicaid and CHIP extension will benefit families and explore the expected impacts of this extension.

Biden's new Welcome Corps program enables regular Americans to sponsor refugees. In this brief, Kelsey Norman and Ana Martin Gil outline a conversation with Craig Damian Smith, co-founder of Pairity, on the Canadian model for private refugee sponsorship and how it can inform the U.S. context.

President Joe Biden's new border rule will route many asylum seekers to Mexico — where migrants face abuses and a growing asylum case backlog. Kelsey Norman and Ana Martín Gil explain why Mexico isn't a "safe third country" for asylum seekers.

As the pandemic persisted across the state, did Texans living in cities have better access to Covid-19 vaccines than those in rural areas? How did race or age factor in? The authors assess the successes and shortfalls of Texas' vaccine distribution strategy, and how to do better next time.

Based on the results of a survey conducted in March 2021, the authors argue that Mexico's asylum system can be strengthened by bolstering transnational cooperation between Mexican civil society organizations and U.S. policymakers and NGOs.

Experts from the Center for Energy Studies offer nine climate policy recommendations for the Biden administration and argue that a bipartisan legislative push could accelerate a move toward significant action on climate change.

This brief assesses the strategic and economic challenges of energy security amid a transition to a lower-carbon energy future.

The high-growth, high-tech sector appears poised to dramatically grow. U.S. policy to support this sector could enhance and hasten its rise, or could destroy a new American dream.

To harness the power of the market for ideas, the federal government must fund the U.S. patent office to 21st century levels and enhance the rights of patent owners.

High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.